Monitor the ICAR 2026 presentations for any new efficacy or safety data on nomlabofusp that could affect the stock. No immediate catalyst from this announcement alone.
Drug in focus
LRMR drug pipeline →nomlabofusp
● Neutral Named in this press release- Impact
- Phase
- Filed/rolling BLA submission
- Time to market
- If the BLA submission is completed by end of 2026 and accepted by the FDA, a PDUFA decision on accelerated approval could come in mid-to-late 2027. A confirmatory Phase 3 trial would still be required for full approval.
- Next catalyst
- None dated
What to watchWatch for completion of the rolling BLA submission (remaining modules expected by end of 2026) and the FDA's subsequent acceptance for filing, which would trigger a PDUFA date assignment. The ICAR 2026 poster presentations on November 12 may provide incremental OLE data but are unlikely to be a major stock-moving event since the data is previously disclosed. The key binary catalyst remains the FDA's accelerated approval decision, likely in 2027.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $2.39entry
- T+1 · 8d ago +5.86%α +3.49% · $2.53
- T+5 · 4d ago +26.36%α +23.76% · $3.02
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Larimar Therapeutics announced that interim clinical data from its ongoing open-label study of nomlabofusp in Friedreich's ataxia, along with new plasma lipid and gene expression analyses, will be presented at the ICAR 2026 conference on November 12. This is a routine scientific update with no new efficacy or safety results disclosed.
Key Facts
- Three poster presentations at ICAR 2026 (Nov 10-13) covering interim data from the open-label study of nomlabofusp, plasma lipid profiles, and gene expression analyses in FA patients.
- Poster session on Thursday, November 12, from 6:30-7:30 p.m. ET.
- Nomlabofusp is Larimar's lead compound for Friedreich's ataxia, a rare disease.
Financial Impact
No financial data disclosed; event is a scientific conference presentation with no material financial impact.
Risk Factors
- No new clinical data released in this press release; the market may have expected more substantive updates.
- Friedreich's ataxia is a rare disease with a small patient population, limiting commercial upside even if nomlabofusp is approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397038 |
Track record
13 reports on LRMR
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
- Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
- Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
- Nov 5, 202611d ago Press Release Neutral 2/10 Viewing Entry $2.39 Now $3.00 +25.52% settles Feb 4
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
- May 14, 202626w ago 8-K Bullish 7/10 No price data
- May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
- Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers